SinoMab Bioscience
- Company typePublic
- Founded2001
- HeadquartersTai Po, Hong Kong SAR China
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
SinoMab Bioscience firmographics
Firmographics- Name
- SinoMab Bioscience
- Legal name
- SinoMab BioScience Limited
- Website
- https://sinomab.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
SinoMab Bioscience industry classification
Industry- Product category
- Immunology biopharmaceutical therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where SinoMab Bioscience is headquartered
LocationHeadquarters
- HQ city
- Tai Po
- HQ country
- Hong Kong SAR China
- HQ region
- Asia
Offices11 records
Markets served
SinoMab Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: SinoMab is a pre-revenue biopharmaceutical company focused on developing novel drugs. The company has not yet commercialized any products. Its flagship product SM03 (Suciraslimab) has completed Phase III clinical trials for rheumatoid arthritis in China and received BLA acceptance from NMPA. Revenue will be generated from pharmaceutical product sales upon regulatory approval and commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
SinoMab Bioscience product offering
Product offeringCore offering
SinoMab BioScience is a clinical-stage biopharmaceutical company that researches, develops, manufactures, and prepares to commercialize novel antibody therapeutics for immunological diseases. Its core offering is a pipeline of first-in-class monoclonal antibody drug candidates, led by SM03 (Suciraslimab, anti-CD22) for rheumatoid arthritis, with supporting candidates SM17, SN1011, SM06, SM09, anti-CGC (hC2) and a bispecific antibody. The company is currently pre-revenue, with future revenue tied to commercial sales of approved biologics.
Product overview
SinoMab BioScience is a biopharmaceutical company developing a portfolio of first-in-class antibody therapeutics for immunological diseases. The core product is SM03 (Suciraslimab), an anti-CD22 antibody for rheumatoid arthritis in Phase III/BLA stage. Key pipeline products include SM17 (anti-IL-25 receptor for asthma, atopic dermatitis, IPF, IBD), SN1011 (BTK inhibitor for pemphigus, NMOSD, MS), SM06 (second-generation anti-CD22), SM09 (anti-CD20), Anti-CGC antibody (hC2 for alopecia areata, vitiligo), and a bispecific antibody for osteoporosis. The company operates five strategic drug identification platforms: B-cell Therapeutic Platform, Alarmins-pathway Therapeutic Platform, Selective-T Cell Therapeutic Platform, Neurological Disease Platform, and Antibody Framework-Patching Humanisation Platform.
Differentiator
Problem solved
Functional benefit
Products and services
- SM03 (Suciraslimab) A global first-in-class anti-CD22 monoclonal antibody with a novel mechanism of B-cell modulation without depletion, being developed for rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, and mild cognitive impairment due to Alzheimer's disease. It is SinoMab's flagship product, with BLA accepted by NMPA in China.
- SM17 (Humanized anti-IL-25 receptor antibody) A novel, first-in-class humanized IgG4-κ monoclonal antibody targeting IL-25 receptor (IL-17RB) to modulate Type II allergic reactions by suppressing Th2 immune responses. Indicated for asthma, atopic dermatitis, idiopathic pulmonary fibrosis, and inflammatory bowel disease.
- SN1011 (BTK inhibitor) A third-generation covalent reversible BTK inhibitor designed for high selectivity with prolonged controlled drug exposure for superior efficacy and safety, indicated for pemphigus, neuromyelitis optica spectrum disorder (NMOSD), and multiple sclerosis (MS).
- SM06 (Humanized Anti-CD22) A second-generation anti-CD22 antibody humanized using SinoMab's proprietary framework-patching technology, with improved safety profiles and reduced immunogenicity, indicated for neuromyelitis optica spectrum disorder.
- SM09 (Humanized Anti-CD20) A framework-patched humanized anti-CD20 antibody targeting an epitope different from market-approved antibodies such as rituximab and obinutuzumab, indicated for non-Hodgkin's lymphoma and autoimmune diseases.
- Anti-CGC antibody (hC2) A novel anti-γc antibody under development for the treatment of alopecia areata and vitiligo, with published preclinical results demonstrating superior efficacy and a differentiated safety profile.
- Bispecific antibody (bsAb) candidate A bispecific antibody candidate derived from the SM03/SM06 lineage under development for the treatment of osteoporosis.
Quantifiable outcome
- 43.3% year-over-year decrease in annual losses for 2025
- +4 more outcomes
Companies that use SinoMab Bioscience
Customer profileSegments1 record
Ideal customer profiles2 records
SinoMab Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
SinoMab Bioscience partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and strategic.
- Travere TherapeuticsminorTravere Therapeutics acquired rights to Everest Medicines' civorebrutinib, a BTK inhibitor for rare kidney diseases, through a $112.5 million upfront deal with potential milestones of up to $1.03 billion. This is related to SinoMab's partnership ecosystem around BTK inhibitors.
- Sun Yat-sen University Institute of Advanced StudiesstrategicSinoMab entered into a strategic cooperation agreement with Sun Yat-sen University Institute of Advanced Studies for collaborative research and development activities in immunological diseases.
- Everest MedicinesstrategicEverest Medicines is a partner of SinoMab and reported positive results for EVER001 in treating primary membranous nephropathy. SinoMab collaborated with Everest Medicines in the development of BTK inhibitors including civorebrutinib.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
SinoMab Bioscience competitors and assessment
Company assessmentDirect peers
- Junshi Biosciences: HK/A-share-listed Chinese biopharma (1877.HK / 688180.SH) focused on innovative antibody therapeutics including immunology; similar in scale, listing status, and R&D pipeline depth to SinoMab.
- Innovent Biologics: China-based antibody specialist (HK: 1801) with approved biologics and a large immunology/oncology pipeline; competes directly with SinoMab for talent, partnerships, and NMPA approvals in autoimmune disease biologics.
- I-Mab Biopharma: US/HK-listed China-focused immunology and immuno-oncology antibody developer with a comparable clinical-stage pipeline strategy and target indications in autoimmune disease.
- Akeso, Inc. Hong Kong-listed (9926.HK) Chinese biopharmaceutical company developing novel antibodies in immunology and oncology, with a similar platform-based pipeline model and Chinese clinical/commercial footprint as SinoMab.
- Everest Medicines: Hong Kong-listed (1952.HK) clinical-stage biopharma developing innovative therapies in immunology and infectious disease; explicitly named as a SinoMab partner on BTK inhibitors (civorebrutinib), making it a closely comparable peer.
Broad incumbents
- Sanofi: Major immunology player behind dupilumab (Dupixent), the dominant biologic in atopic dermatitis and Type 2 inflammation — directly relevant competitor to SM17 in AD, asthma and CRSwNP.
- Sino Biopharmaceutical: Established Hong Kong-listed (1177.HK) Chinese pharmaceutical major with a sizeable immunology and biologics business; represents a scaled incumbent in the same therapeutic and geographic arena as SinoMab.
- BeiGene (now BeOne Medicines): Large global oncology-focused biopharma with significant China R&D and commercial operations; a broader incumbent in the same HK-listed innovative biologics space, with overlapping antibody capabilities.
- AbbVie: Global leader in immunology (Humira, Rinvoq, Skyrizi) and a benchmark competitor in the RA/atopic dermatitis/asthma indications SinoMab targets with SM03 and SM17.
- Eli Lilly: Global biopharma with a leading immunology franchise (Taltz, Olumiant) and active investment in autoimmune antibody therapeutics, competing across the same indications SinoMab is pursuing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
SinoMab Bioscience social profiles
Digital presenceSinoMab Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
SinoMab Bioscience leadership team
Management profileNumber of profiles
Profiles6 records
SinoMab Bioscience subsidiaries and ownership
Company hierarchySubsidiaries9 records
SinoMab Bioscience funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SinoMab Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SinoMab Bioscience
What does SinoMab Bioscience do?
SinoMab BioScience is a clinical-stage biopharmaceutical company that researches, develops, manufactures, and prepares to commercialize novel antibody therapeutics for immunological diseases. Its core offering is a pipeline of first-in-class monoclonal antibody drug candidates, led by SM03 (Suciraslimab, anti-CD22) for rheumatoid arthritis, with supporting candidates SM17, SN1011, SM06, SM09, anti-CGC (hC2) and a bispecific antibody. The company is currently pre-revenue, with future revenue tied to commercial sales of approved biologics.
Is SinoMab Bioscience a public or private company?
SinoMab Bioscience is a public company. It is classified as public and is currently operating.
When was SinoMab Bioscience founded?
SinoMab Bioscience was founded in 2001. It employs 101 to 250 people.
Where is SinoMab Bioscience based?
SinoMab Bioscience is headquartered in Tai Po, Hong Kong SAR China, in the Asia region.
How does SinoMab Bioscience make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are SinoMab Bioscience's main competitors?
Direct peers on record are Junshi Biosciences, Innovent Biologics, I-Mab Biopharma, Akeso, Inc. and Everest Medicines. Broad incumbents are Sanofi, Sino Biopharmaceutical, BeiGene (now BeOne Medicines), AbbVie and Eli Lilly.
Does SinoMab Bioscience have an API?
No public API is recorded for SinoMab Bioscience.
What industry is SinoMab Bioscience in?
SinoMab Bioscience's product category is Immunology biopharmaceutical therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.